...
  • 主题
高级搜索  >
历史搜索 清空历史
首页> 外文期刊>Circulation journal >Elevated serum heart-type fatty acid-binding protein in the convalescent stage predicts long-term outcome in patients surviving acute myocardial infarction
【24h】

Elevated serum heart-type fatty acid-binding protein in the convalescent stage predicts long-term outcome in patients surviving acute myocardial infarction

机译：康复期血清心脏型脂肪酸结合蛋白升高可预测急性心肌梗死患者的长期预后

获取原文
获取原文并翻译 | 示例
           
页面导航
  • 摘要
  • 著录项
  • 相似文献
  • 相关主题

摘要

Background: Little is known about the prognostic significance of elevated serum heart-type fatty acid-binding protein (H-FABP) in post-acute myocardial infarction (post-AMI) patients. Methods and Results: A total of 1,283 post-AMI patients with available serum samples collected in the convalescent stage were studied. During a median follow-up period of 1,785 days, 176 patients (14%) had adverse events (all-cause mortality, n=81; non-fatal MI, n=44; readmission for heart failure [HF], n=51). Patients were divided into 2 groups according to a serum H-FABP level of 6.08 ng/ml, which was determined to be the optimal cut-off for discriminating all-cause mortality based on the maximum value of the area under the receiver operating characteristic curve. Patients with elevated H-FABP (>6.08 ng/ml, n=224) had a significantly higher incidence of death (18.3% vs. 3.8%, P<0.001) and readmission for HF (10.3% vs. 2.6%, P<0.001), but not of non-fatal MI (4.5% vs. 3.2%, P=0.187), compared to those with H-FABP <6.08 ng/ml. Multivariate Cox regression analysis indicated that elevated serum H-FABP was associated with an increased risk of mortality (hazard ratio [HR], 1.91; 95% confidence interval [CI]: 1.03-3.51, P=0.039) and readmission for HF (HR, 2.49; 95% CI: 1.15-5.39, P=0.020). Conclusions: Elevated serum H-FABP during the convalescent stage of AMI predicted long-term mortality and readmission for HF after survival discharge in the post-AMI patients.
机译：背景：对急性心肌梗死（AMI后）患者血清心脏型脂肪酸结合蛋白（H-FABP）升高的预后意义了解甚少。方法和结果：共研究了1,283名AMI后患者在康复期收集的可用血清样品。在中位随访期1,785天中，有176例患者（占14％）发生不良事件（全因死亡率，n = 81;非致命性MI，n = 44;因心力衰竭再次入院[HF]，n = 51） ）。根据血清H-FABP水平6.08 ng / ml将患者分为两组，根据受试者工作特征曲线下面积的最大值，将其确定为区分全因死亡率的最佳临界值。 H-FABP（> 6.08 ng / ml，n = 224）升高的患者死亡和心衰再入院率（10.3％vs. 2.6％，P <0.001）显着更高（18.3％vs. 3.8％，P <0.001）与H-FABP <6.08 ng / ml的MI相比，非致命MI的0.001）（而非非致命MI）（4.5％vs. 3.2％，P = 0.187）。多元Cox回归分析表明，血清H-FABP升高与死亡风险增加（危险比[HR]，1.91; 95％置信区间[CI]：1.03-3.51，P = 0.039）和HF（HR ，2.49; 95％CI：1.15-5.39，P ＝ 0.020）。结论：AMI恢复期血清H-FABP升高可预测AMI后患者出院后长期死亡和HF再入院。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

  • 客服微信

  • 服务号